Fig. 1From: The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBSValue of emerging therapeutics in RCC. We measured value of emerging therapeutics in RCC using ASCO value framework and ESMO-MCBSBack to article page